Skip to main content
. Author manuscript; available in PMC: 2017 Jul 13.
Published in final edited form as: Clin Cancer Res. 2016 Jan 18;22(11):2650–2658. doi: 10.1158/1078-0432.CCR-15-2160

Fig. 1. MK-2206 induced apoptosis in ER+ breast cancer cells in vitro.

Fig. 1

a, MK-2206 induced apoptosis in ER+ breast cancer cell lines. Mutations in PIK3CA and PTEN, and HER2 amplification were indicated. Cells cultured under estrogen-deprived conditions for 1–3 weeks were treated with MK-2206 250 nmol/L, followed by apoptosis assay by TUNEL. The ER- cell line MDA-MB-231 served as a negative control. b, Estrogen suppressed apoptotic induction by MK-2206 in some ER+ breast cancer cell lines. Cells cultured without or with 10 nmol/L estradiol (E2) were treated with MK-2206 250nmol/L for 4 days followed by apoptosis assay. c, LTED ER+ cell lines were resistant to MK-2206 but sensitive to fulvestrant plus MK-2206 in 2 of the 4 lines tested. ER+ LTED cells were pre-treated with fulvestrant for 3 days prior to the addition of MK-2206 for 4 days followed by apoptosis assessment. Results were from at least 3 replicates for each treatment condition. Significant activation of apoptosis was indicated (*, p<0.05). d, Western Blot of ER and PI3K pathway markers for LTED and parental ER+ cell lines cultured under estrogen deprivation.